CYBERDYNE Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Yoshiyuki Sankai

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	18.3yrs
CEO ownership	38.2%
Management average tenure	no data
Board average tenure	14.1yrs

Recent management updates

Recent updates

CEO

Yoshiyuki Sankai (65 yo)

18.3yrs

Tenure

Dr. Yoshiyuki Sankai has been the President and Chief Executive Officer of CYBERDYNE Inc. since February 2006 and also serves as its Chairman. Dr. Sankai established CYBERDYNE, Inc. in June 2004. He has be...

Board Members

Name	Position	Tenure	Compensation	Ownership
Yoshiyuki Sankai	Chairman	19.9yrs	no data	38.24% ¥ 16.3b
Shinji Honda	Executive Director & COO	less than a year	no data	no data
Shinji Uga	Head of Corporate Department & Director	15.3yrs	no data	no data
Cees Vellekoop	Outside Audit & Supervisory Board Member	16.9yrs	no data	no data
Hikari Imai	Independent Outside Director	8.9yrs	no data	no data
Kenichiro Okamura	Independent Outside Audit & Supervisory Board Member	12.9yrs	no data	no data
Hiroaki Kawamoto	Director	19.9yrs	no data	no data
Yutaka Fujitani	Independent Outside Audit & Supervisory Board Member	12.9yrs	no data	no data
Akira Matsumura	Independent Outside Director	no data	no data	0.0024% ¥ 1.0m

14.1yrs

Average Tenure

65yo

Average Age

Experienced Board: 7779's board of directors are seasoned and experienced ( 14.1 years average tenure).

CYBERDYNE Management

Management criteria checks 1/4

Key information

Recent management updates

CYBERDYNE Inc., Annual General Meeting, Jun 22, 2023

Cyberdyne Inc. Announces Yuzo Toda Passed Away on December 27, 2022, and Retired from the Position of Director on the Same Day

Less than half of directors are independent

CYBERDYNE Inc., Annual General Meeting, Jun 30, 2022

Less than half of directors are independent

CYBERDYNE Inc., Annual General Meeting, Jun 24, 2021

Recent updates

Price target decreased by 21% to JP¥320

CYBERDYNE Inc. to Report Fiscal Year 2024 Results on May 15, 2024

Third quarter 2024 earnings released: JP¥1.65 loss per share (vs JP¥0.93 loss in 3Q 2023)

CYBERDYNE Inc. to Report Q3, 2024 Results on Feb 14, 2024

Consensus EPS estimates fall by 463%, revenue upgraded

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings released: JP¥4.42 loss per share (vs JP¥0.13 profit in 2Q 2023)

CYBERDYNE Inc. to Report Q2, 2024 Results on Nov 14, 2023

CYBERDYNE Inc. to Report First Half, 2024 Results on Nov 14, 2023

First quarter 2024 earnings released: EPS: JP¥1.56 (vs JP¥1.12 in 1Q 2023)

New minor risk - Share price stability

CYBERDYNE Inc. to Report Q1, 2024 Results on Aug 14, 2023

Consensus EPS estimates fall by 783%

Forecast breakeven date pushed back to 2025

Forecast breakeven date moved forward to 2024

Forecast breakeven date moved forward to 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast breakeven date pushed back to 2026

Consensus EPS estimates fall by 449%, revenue upgraded

CYBERDYNE Inc., Annual General Meeting, Jun 22, 2023

CYBERDYNE Inc. to Report Fiscal Year 2023 Results on May 15, 2023

Third quarter 2023 earnings released: JP¥0.93 loss per share (vs JP¥0.74 loss in 3Q 2022)

CYBERDYNE Inc. to Report Q3, 2023 Results on Feb 14, 2023

Cyberdyne Inc. Announces Yuzo Toda Passed Away on December 27, 2022, and Retired from the Position of Director on the Same Day

Consensus EPS estimates increase by 353%

Price target decreased to JP¥560

Less than half of directors are independent

Consensus forecasts updated

Price target decreased to JP¥780

CYBERDYNE Inc. to Report First Half, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: EPS: JP¥1.13 (vs JP¥1.28 loss in 1Q 2022)

CYBERDYNE Inc. to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CYBERDYNE Inc., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

Forecast breakeven date pushed back to 2024

Price target increased to JP¥810

Less than half of directors are independent

Now 23% undervalued after recent price drop

Price target increased to JP¥843

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CYBERDYNE Inc. to Report Fiscal Year 2022 Results on May 13, 2022

Forecast breakeven date pushed back to 2023

Price target decreased to JP¥745

Second quarter 2022 earnings released: JP¥0.70 loss per share (vs JP¥1.38 profit in 2Q 2021)

CYBERDYNE Inc. Announces Medical HAL Single Joint Type Receives Medical Device Approval from Australian Therapeutic Goods Administration, Department of Health

CYBERDYNE Inc. (TSE:7779) acquired C2,Inc.

First quarter 2022 earnings released: JP¥1.28 loss per share (vs JP¥0.60 loss in 1Q 2021)

Cyberdyne Inc. Preliminary Results of Medical Hal Lower Limb Type Stroke Clinical Trial

Price target decreased to JP¥845

Full year 2021 earnings released: JP¥0.27 loss per share (vs JP¥0.71 loss in FY 2020)

New 90-day low: JP¥611

CYBERDYNE Inc., Annual General Meeting, Jun 24, 2021

CYBERDYNE Inc Forms Strategic Partnership with Cellsource Co., Ltd

Third quarter 2021 earnings released: JP¥0.40 loss per share (vs JP¥0.46 profit in 3Q 2020)

Revenue and earnings miss expectations

Analysts lower EPS estimates to -JP¥1.36

New 90-day low: JP¥644

CYBERDYNE Inc. to Report Q3, 2021 Results on Feb 12, 2021

CYBERDYNE Inc. Medical Hal Obtains Approval from Singapore Health Science Authority

CYBERDYNE Inc. Announces that Stroke Clinical Trial on Medical HAL is Complete

Price target raised to JP¥1,075

Cyberdyne Inc. Exports Six Units of Its Wearable Cyborg Hal (Three Units of Lower Limb Type, Two Units of Single Joint Type, One Unit of Lumbar Type) to Institute of Brain & Spine Hospital

CYBERDYNE Inc. Obtains a Medical Device Approval for HAL for Medical Use Lower Limb Type

Malaysian Public Social Security Organization Expands Cybernics Treatment to 4 Major Sites in Malaysia

CYBERDYNE Inc. to Report Q2, 2021 Results on Nov 13, 2020

CYBERDYNE Inc. Announces Marketing Clearance From U.S. FDA for Medical HAL Expands To Stroke And Progressive Neuromuscular Disease

CYBERDYNE Inc. to Report Q1, 2021 Results on Aug 14, 2020

CEO